Evofem Biosciences Net Income 2013-2022 | EVFM

Evofem Biosciences net income from 2013 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Evofem Biosciences Annual Net Income
(Millions of US $)
2021 $-206
2020 $-142
2019 $-80
2018 $-126
2017 $-109
2016 $-13
2015 $-43
2014 $-11
2013 $-15
2012 $-8
Evofem Biosciences Quarterly Net Income
(Millions of US $)
2022-03-31 $-32
2021-12-31 $-53
2021-09-30 $-74
2021-06-30 $-33
2021-03-31 $-46
2020-12-31 $-41
2020-09-30 $-30
2020-06-30 $-53
2020-03-31 $-19
2019-12-31 $-13
2019-09-30 $-14
2019-06-30 $-35
2019-03-31 $-18
2018-12-31 $-15
2018-09-30 $-18
2018-06-30 $-23
2018-03-31 $-69
2017-12-31 $-21
2017-09-30 $-75
2017-06-30 $-7
2017-03-31 $-6
2016-12-31 $-2
2016-09-30 $-2
2016-06-30 $-3
2016-03-31 $-6
2015-12-31 $-10
2015-09-30 $-17
2015-06-30 $-9
2015-03-31 $-7
2014-12-31 $-3
2014-09-30 $-4
2014-06-30 $-2
2014-03-31 $-2
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.005B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.111B 10.23
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.588B 16.71
Biohaven Pharmaceutical Holding (BHVN) United States $10.141B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.081B 0.00
Arcus Biosciences (RCUS) United States $1.832B 46.46
Emergent Biosolutions (EBS) United States $1.646B 7.05
Myovant Sciences (MYOV) United Kingdom $1.264B 0.00
Zymeworks (ZYME) Canada $0.364B 0.00
Gelesis Holdings (GLS) United States $0.116B 0.00
Ambrx Biopharma (AMAM) United States $0.111B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00